US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Caris Life Sciences, Inc.

24.34

+0.30001.25%

Post-market: 24.340.00000.00%16:10 EDT

Volume:1.80M

Turnover:43.87M

Market Cap:6.87B

PE:65.43

High:24.67

Open:24.16

Low:24.09

Close:24.04

52wk High:34.75

52wk Low:14.19

Shares:282.15M

Float Shares:116.00M

Volume Ratio:0.42

T/O Rate:1.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.3720

EPS(LYR):-3.2200

ROE:20.13%

ROA:8.77%

PB:11.61

PE(LYR):-7.56

Loading ...

Overview Company News Filings

Earnings Flash (CAI) Caris Life Sciences Posts Q1 EPS $0.0, vs. FactSet Est of -$0.02

MT Newswires Live

Caris Life Sciences Q1 revenue rises on demand for molecular profiling services

Caris Q1 net loss narrows to $0.5 million; revenue rises 79% to $216 million

Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate

Benzinga Earnings

Caris Life Sciences Inc - Reaffirms FY2026 Revenue Guidance of $1.0 Bln-$1.02 Bln

THOMSON REUTERS

CAI Launches Next Chapter with Investment from JLL Partners

Press Release: AudioCodes Reports First Quarter 2026 Results

BRIEF-Caris Life Sciences Receives Moldx Approval For Caris Chromoseq, Advancing Access To Comprehensive Genomic Profiling For Myeloid Malignancies

Caris wins MolDX approval for ChromoSeq myeloid malignancy genome profiling test

Earning Preview: Caris Life Sciences, Inc. revenue this quarter is expected to decrease by 28%, and institutional views are broadly bullish

Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients

Press Release: Horn Williamson Rebrands as Horn Williamson & Collins, Adds Matthew C. Collins as Named Partner

A Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months

Simply Wall St.

Caris Life Sciences announces annual shareholder meeting

Caris Life Sciences to report first-quarter financial results, host webcast

Hua An Insurance Announces CEO Resignation and Appointment of Interim Leader

CAI Corp Updates Investors on March 2026 Net Asset Value

U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines

Caris Life Sciences Initiated at Buy by Jefferies

Jefferies Initiates Caris Life Sciences at Buy With $28 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/CAI/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAI\",,,,,undefined,":{"symbol":"CAI","market":"US","secType":"STK","nameCN":"Caris Life Sciences, Inc.","latestPrice":24.34,"timestamp":1789156800000,"preClose":24.04,"halted":0,"volume":1797466,"hourTrading":{"tag":"盘后","latestPrice":24.34,"preClose":24.34,"latestTime":"16:10 EDT","volume":41793,"amount":1017289.055055,"timestamp":1789157405079,"change":0,"changeRate":0,"amplitude":0.003739},"delay":0,"changeRate":0.01247920133111484,"floatShares":115999999,"shares":282146923,"eps":0.372,"marketStatus":"Post-Mkt","change":0.3,"latestTime":"09-11 16:32:48 EDT","open":24.16,"high":24.67,"low":24.09,"amount":43867470,"amplitude":0.024126,"askPrice":25.2,"askSize":100,"bidPrice":24.16,"bidSize":3,"shortable":3,"etf":0,"ttmEps":0.372,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1750219200000,"exchange":"NASDAQ","adjPreClose":24.04,"preHourTrading":{"tag":"盘前","latestPrice":24.05,"preClose":24.04,"latestTime":"09:28 EDT","volume":927,"amount":22502.048985,"timestamp":1789133332030,"change":0.01,"changeRate":0.000416,"amplitude":0.011231},"postHourTrading":{"tag":"盘后","latestPrice":24.34,"preClose":24.34,"latestTime":"16:10 EDT","volume":41793,"amount":1017289.055055,"timestamp":1789157405079,"change":0,"changeRate":0,"amplitude":0.003739},"volumeRatio":0.417946,"impliedVol":0.4636,"impliedVolPercentile":0.0438},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAI\",,,,,undefined,":{"symbol":"CAI","floatShares":115999999,"roa":"8.77%","roe":"20.13%","lyrEps":-3.22,"volumeRatio":0.417946,"shares":282146923,"dividePrice":0,"high":24.67,"amplitude":0.024126,"preClose":24.04,"low":24.09,"week52Low":14.19,"pbRate":"11.61","psRate":"6.94","week52High":34.75,"institutionHeld":0,"latestPrice":24.34,"committee":-0.941748,"eps":0.372,"divideRate":0,"volume":1797466,"delay":0,"ttmEps":0.372,"open":24.16,"prevYearClose":26.98,"prevWeekClose":25.07,"prevMonthClose":25.49,"prevQuarterClose":17.82,"fiveDayClose":25.32,"twentyDayClose":22.18,"sixtyDayClose":17.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"CAI","fiscalQuarterEnding":"2026/06","expectedEps":-0.01,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2026-05-07","symbol":"CAI","fiscalQuarterEnding":"2026/03","expectedEps":-0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2026-02-26","symbol":"CAI","fiscalQuarterEnding":"2025/12","expectedEps":0.01,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":0.28},{"market":"US","date":"2026-01-12","symbol":"CAI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1768194000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.3333,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":12,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CAI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CAI","date":"2026-09-10","current":65.430108,"percent":0.786127,"low":-88.150592,"twenty":-40.914563,"median":-30.48612,"eighty":67.251929,"high":165.024421,"avg":1.593203,"sd":72.202126,"marketCap":6790762319},"quantilePoints":[{"date":"2021-09-17","current":9.368604,"twenty":4.110509,"median":11.370572,"eighty":29.049822,"marketCap":968451299},{"date":"2021-09-24","current":9.368604,"twenty":4.156375,"median":11.370572,"eighty":29.049822,"marketCap":968451299},{"date":"2021-10-01","current":9.376989,"twenty":4.213229,"median":11.370724,"eighty":29.050072,"marketCap":969318155},{"date":"2021-10-07","current":9.380344,"twenty":4.238981,"median":11.370724,"eighty":29.050072,"marketCap":969664897},{"date":"2021-10-15","current":9.378667,"twenty":4.266668,"median":11.380332,"eighty":29.050823,"marketCap":969491526},{"date":"2021-10-22","current":9.378667,"twenty":4.284214,"median":11.383933,"eighty":29.120677,"marketCap":969491526},{"date":"2021-10-29","current":9.382021,"twenty":4.305342,"median":11.383933,"eighty":29.120677,"marketCap":969838269},{"date":"2021-11-05","current":9.383698,"twenty":4.32826,"median":11.383933,"eighty":29.120677,"marketCap":970011640},{"date":"2021-11-09","current":6.915273,"twenty":4.340793,"median":11.383933,"eighty":29.120677,"marketCap":961803774},{"date":"2025-06-20","current":-27.445954,"twenty":9.383698,"median":19.818182,"eighty":28.465108,"marketCap":7736739976},{"date":"2025-06-27","current":-26.374479,"twenty":9.383698,"median":19.818182,"eighty":28.465108,"marketCap":7434701838},{"date":"2025-07-03","current":-26.167427,"twenty":9.383698,"median":19.818182,"eighty":28.465108,"marketCap":7376335954},{"date":"2025-07-11","current":-26.246304,"twenty":9.383698,"median":19.818182,"eighty":28.465108,"marketCap":7398570576},{"date":"2025-07-18","current":-30.845816,"twenty":9.382356,"median":19.818182,"eighty":28.465108,"marketCap":8695126991},{"date":"2025-07-25","current":-29.076014,"twenty":9.380344,"median":19.818182,"eighty":28.465108,"marketCap":8196237652},{"date":"2025-08-01","current":-27.685808,"twenty":9.378667,"median":19.818182,"eighty":28.465108,"marketCap":7804352434},{"date":"2025-08-08","current":-28.188649,"twenty":9.377325,"median":19.778051,"eighty":28.363181,"marketCap":7946098151},{"date":"2025-08-15","current":-37.278729,"twenty":9.37397,"median":15.016779,"eighty":28.059445,"marketCap":10402480346},{"date":"2025-08-22","current":-38.41755,"twenty":9.371958,"median":14.936518,"eighty":27.857377,"marketCap":10720263606},{"date":"2025-08-29","current":-38.528408,"twenty":9.368604,"median":14.909765,"eighty":27.685829,"marketCap":10751198260},{"date":"2025-09-05","current":-36.633734,"twenty":9.365249,"median":14.888362,"eighty":27.527351,"marketCap":10222496907},{"date":"2025-09-12","current":-34.47703,"twenty":9.360553,"median":14.824668,"eighty":27.293717,"marketCap":9620677282},{"date":"2025-09-19","current":-33.690942,"twenty":7.38442,"median":14.763781,"eighty":26.71778,"marketCap":9401322465},{"date":"2025-09-26","current":-29.962061,"twenty":-25.851919,"median":14.718778,"eighty":26.293958,"marketCap":8360793206},{"date":"2025-10-03","current":-29.941905,"twenty":-26.165455,"median":11.559155,"eighty":25.35941,"marketCap":8355168724},{"date":"2025-10-10","current":-31.504003,"twenty":-26.421805,"median":11.424439,"eighty":24.232627,"marketCap":8791066116},{"date":"2025-10-17","current":-32.199389,"twenty":-27.275648,"median":11.239535,"eighty":23.200759,"marketCap":8985110761},{"date":"2025-10-24","current":-31.907126,"twenty":-27.85145,"median":10.925198,"eighty":22.717001,"marketCap":8903555765},{"date":"2025-10-31","current":-31.413301,"twenty":-29.076014,"median":10.711237,"eighty":22.474875,"marketCap":8765755945},{"date":"2025-11-07","current":-37.133331,"twenty":-29.570316,"median":10.518408,"eighty":22.474875,"marketCap":6943635775},{"date":"2025-11-14","current":-36.66558,"twenty":-29.872671,"median":10.079921,"eighty":22.474875,"marketCap":6856170228},{"date":"2025-11-21","current":-36.258185,"twenty":-30.266418,"median":9.392084,"eighty":22.474875,"marketCap":6779990559},{"date":"2025-11-28","current":-38.521493,"twenty":-30.494182,"median":9.38873,"eighty":22.474875,"marketCap":7203210944},{"date":"2025-12-05","current":-42.731244,"twenty":-30.709853,"median":9.383698,"eighty":22.390599,"marketCap":7990400859},{"date":"2025-12-12","current":-40.045453,"twenty":-31.411285,"median":9.382021,"eighty":21.98126,"marketCap":7488179336},{"date":"2025-12-19","current":-42.037163,"twenty":-31.770064,"median":9.380344,"eighty":21.917049,"marketCap":7860613274},{"date":"2025-12-26","current":-42.610535,"twenty":-32.023314,"median":9.378667,"eighty":21.917049,"marketCap":7967829105},{"date":"2026-01-02","current":-40.709356,"twenty":-33.019743,"median":9.376989,"eighty":21.917049,"marketCap":7612323982},{"date":"2026-01-09","current":-42.625623,"twenty":-33.660707,"median":9.375312,"eighty":21.911699,"marketCap":7970650574},{"date":"2026-01-16","current":-40.920598,"twenty":-34.325859,"median":9.371958,"eighty":14.957921,"marketCap":7651824551},{"date":"2026-01-23","current":-38.55167,"twenty":-35.122025,"median":9.368604,"eighty":14.936518,"marketCap":7208853882},{"date":"2026-01-30","current":-38.023565,"twenty":-36.062032,"median":9.366927,"eighty":14.901739,"marketCap":7110102459},{"date":"2026-02-06","current":-32.063522,"twenty":-36.001677,"median":9.365249,"eighty":14.891037,"marketCap":5995622113},{"date":"2026-02-13","current":-31.158199,"twenty":-36.001677,"median":9.358541,"eighty":14.824668,"marketCap":5826333959},{"date":"2026-02-20","current":-31.459973,"twenty":-36.001677,"median":6.916509,"eighty":14.791194,"marketCap":5882763344},{"date":"2026-02-27","current":-79.83495,"twenty":-36.095748,"median":-25.920936,"eighty":14.746309,"marketCap":5435802106},{"date":"2026-03-06","current":-79.767155,"twenty":-36.689445,"median":-26.167427,"eighty":11.649494,"marketCap":5431186043},{"date":"2026-03-13","current":-73.417324,"twenty":-37.230355,"median":-26.433637,"eighty":11.50157,"marketCap":4998838767},{"date":"2026-03-20","current":-78.065566,"twenty":-37.948121,"median":-27.000565,"eighty":11.33727,"marketCap":5315328276},{"date":"2026-03-27","current":-76.073463,"twenty":-38.51833,"median":-27.544452,"eighty":11.081046,"marketCap":5179689915},{"date":"2026-04-02","current":-79.393635,"twenty":-38.55167,"median":-28.040754,"eighty":10.896141,"marketCap":5405753850},{"date":"2026-04-10","current":-79.684151,"twenty":-38.689657,"median":-29.080944,"eighty":10.700671,"marketCap":5425534444},{"date":"2026-04-17","current":-84.66441,"twenty":-39.396638,"median":-29.538348,"eighty":10.447088,"marketCap":5764630347},{"date":"2026-04-24","current":-82.156794,"twenty":-39.864388,"median":-29.869713,"eighty":9.998035,"marketCap":5593891765},{"date":"2026-05-01","current":-78.877164,"twenty":-40.407582,"median":-30.254324,"eighty":9.392084,"marketCap":5370588355},{"date":"2026-05-08","current":165.024421,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5608024892},{"date":"2026-05-15","current":126.854033,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":4310880598},{"date":"2026-05-22","current":132.593658,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":4505930278},{"date":"2026-05-29","current":138.666015,"twenty":-40.929651,"median":-30.496198,"eighty":9.387052,"marketCap":4712287185},{"date":"2026-06-05","current":143.740176,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":4884722409},{"date":"2026-06-12","current":149.72935,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5088252510},{"date":"2026-06-18","current":148.564789,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5048677212},{"date":"2026-06-26","current":155.552158,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5286128996},{"date":"2026-07-02","current":155.968073,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5300263031},{"date":"2026-07-10","current":148.647972,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":5051504019},{"date":"2026-07-17","current":137.085538,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":4658577853},{"date":"2026-07-24","current":130.181352,"twenty":-40.920598,"median":-30.491159,"eighty":9.387052,"marketCap":4423952876},{"date":"2026-07-31","current":133.841403,"twenty":-40.929651,"median":-30.496198,"eighty":9.387052,"marketCap":4548332382},{"date":"2026-08-07","current":53.756202,"twenty":-40.929651,"median":-30.496198,"eighty":9.389065,"marketCap":5651658300},{"date":"2026-08-14","current":59.618217,"twenty":-40.929651,"median":-30.496198,"eighty":9.397451,"marketCap":6267961225},{"date":"2026-08-21","current":66.069241,"twenty":-40.929651,"median":-30.496198,"eighty":58.231247,"marketCap":6946189671},{"date":"2026-08-28","current":70.907509,"twenty":-40.914563,"median":-30.48612,"eighty":61.166462,"marketCap":7454861006},{"date":"2026-09-04","current":68.058307,"twenty":-40.914563,"median":-30.48612,"eighty":66.649833,"marketCap":7155310109},{"date":"2026-09-10","current":64.590881,"twenty":-40.914563,"median":-30.48612,"eighty":67.251929,"marketCap":6790762319}],"updateTime":1789158768549},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAI\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633704091","title":"Earnings Flash (CAI) Caris Life Sciences Posts Q1 EPS $0.0, vs. FactSet Est of -$0.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2633704091","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633704091?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:17","pubTimestamp":1778188622,"startTime":"0","endTime":"0","summary":"Earnings Flash (CAI) Caris Life Sciences Posts Q1 EPS $0.0, vs. FactSet Est of -$0.02","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAI.AU","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172034","title":"Caris Life Sciences Q1 revenue rises on demand for molecular profiling services","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172034","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172034?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:52","pubTimestamp":1778187167,"startTime":"0","endTime":"0","summary":"Caris Life Sciences Q1 revenue rises on demand for molecular profiling servicesOverviewPrecision medicine firm's Q1 revenue rose 79% yr/yr, driven by molecular profiling servicesGross margin improved ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1K3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633550171","title":"Caris Q1 net loss narrows to $0.5 million; revenue rises 79% to $216 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633550171","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633550171?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:18","pubTimestamp":1778185134,"startTime":"0","endTime":"0","summary":"Caris Life Sciences Q1 2026 revenue rose 79% to $216 million.Net loss narrowed to $0.5 million, while gross margin expanded 18 percentage points to 65%.Molecular profiling revenue climbed 85% to $210.8 million on 15% higher volume of 52,800 completed clinical cases.Adjusted EBITDA swung to a gain of $26.2 million, free cash flow turned positive at $22.5 million, cash and marketable securities totaled $825.7 million.Caris reaffirmed 2026 revenue guidance of $1 billion to $1.02 billion, expecting molecular profiling revenue of $925 million to $935 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLb6pPTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633296179","title":"Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633296179","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633296179?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184956,"startTime":"0","endTime":"0","summary":"Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst consensus estimate of $210.292 million by 2.80 percent.  This is a 78.78 percent increase over sales of $120.915","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52389460/caris-life-sciences-q1-sales-216-174m-beat-210-292m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633317945","title":"Caris Life Sciences Inc - Reaffirms FY2026 Revenue Guidance of $1.0 Bln-$1.02 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633317945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633317945?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXC56491:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633994239","title":"CAI Launches Next Chapter with Investment from JLL Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2633994239","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633994239?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:00","pubTimestamp":1777996800,"startTime":"0","endTime":"0","summary":"INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, today announced thatit has entered into an agreement withJLLPartners, a New York-based middle-market private equity firm focused on investing in the healthcare, industrials, and business services sectors, to support the next phase of growth for CAI.This partnership positions CAI to expand its global footprint, invest in next-generation technologies, and enhance its service offerings to better support customers operating in complex, technically demanding, and highly regulated environments.About CAICAI is a professional services firm composed of engineering, quality, and operations experts dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments. With deep roots in CQV , CAI has evolved over the past 30 years alongside the industries it serves,","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2972509/CAI_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2972509/CAI_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cai-launches-next-chapter-with-investment-from-jll-partners-302762786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0054578231.USD","CAI","JLL","BK4079","BK4104","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991014","title":"Press Release: AudioCodes Reports First Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991014","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991014?lang=en_us&edition=fundamental","pubTime":"2026-05-05 14:00","pubTimestamp":1777960800,"startTime":"0","endTime":"0","summary":"-- Quarterly revenues increased by 2.9% year-over-year to $62.1 million;-- Quarterly services revenues increased by 4.3% year-over-year to $34.0. Revenues for the first quarter of 2026 were $62.1 million compared to $60.4 million for the first quarter of 2025.Net income was $2.0 million, or $0.07 per diluted share, for the first quarter of 2026 compared to net income of $4.0 million, or $0.13 per diluted share, for the first quarter of 2025.On a Non-GAAP basis, net income was $3.8 million, or $0.14 per diluted share, for the first quarter of 2026 compared to $4.7 million, or $0.15 per diluted share, for the first quarter of 2025.Net cash provided by operating activities was $12.8 million for the first quarter of 2026. Cash and cash equivalents, short-term bank deposits, short-term marketable securities, and long-term financial investments were $68.1 million as of March 31, 2026 compared to $75.7 million as of December 31, 2025. The decrease in cash and cash equivalents, short-term bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","ARTY","AUDC","BK4588","ARR","BK4587","CHAT","AI","BK4104","BK4528","BK4585","AGIX","BK4023","CAI","BK4543","BK4020","BK4551","BK4139","AIYY","BK4110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632595318","title":"BRIEF-Caris Life Sciences Receives Moldx Approval For Caris Chromoseq, Advancing Access To Comprehensive Genomic Profiling For Myeloid Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2632595318","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632595318?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:33","pubTimestamp":1777897996,"startTime":"0","endTime":"0","summary":"BRIEF-Caris Life Sciences Receives Moldx Approval For Caris Chromoseq, Advancing Access To Comprehensive Genomic Profiling For Myeloid MalignanciesMay 4 (Reuters) - Caris Life Sciences Inc CAI.O:CARIS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632539489","title":"Caris wins MolDX approval for ChromoSeq myeloid malignancy genome profiling test","url":"https://stock-news.laohu8.com/highlight/detail?id=2632539489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632539489?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:31","pubTimestamp":1777897899,"startTime":"0","endTime":"0","summary":"Caris Life Sciences received MolDX approval on May 4, 2026 for Caris ChromoSeq, supporting broader Medicare coverage pathway for its whole-genome tumor profiling test in myeloid malignancies.MolDX, administered by Palmetto GBA for CMS, cleared the assay based on clinical validity and utility review.ChromoSeq is positioned as ultra-deep whole-genome sequencing to consolidate multiple diagnostic tests into one report for diseases such as AML, MDS, MPN.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL5HpPYY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121367051","title":"Earning Preview: Caris Life Sciences, Inc. revenue this quarter is expected to decrease by 28%, and institutional views are broadly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1121367051","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121367051?lang=en_us&edition=fundamental","pubTime":"2026-05-01 02:39","pubTimestamp":1777574345,"startTime":"0","endTime":"0","summary":"Abstract Caris Life Sciences, Inc. is scheduled to announce quarterly results on May 7, 2026 Post Market, with current estimates pointing to revenue of about 210.29 million US dollars and adjusted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Caris Life Sciences, Inc. revenue this quarter is expected to decrease by 28%, and institutional views are broadly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631151191","title":"Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2631151191","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631151191?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:34","pubTimestamp":1777466041,"startTime":"0","endTime":"0","summary":"Caris Life Sciences published a peer-reviewed validation study on April 29, 2026 in Neuro-Oncology Advances for an AI-derived signature aimed at guiding temozolomide use in glioblastoma.Results were presented as published findings, with no future presentation disclosed.Study validated model’s ability to infer MGMT promoter methylation status from Caris NGS data, supporting treatment selection for IDH-wild type glioblastoma patients receiving temozolomide.Caris reported signature improved separation of survival outcomes across patient subgroups versus traditional MGMT testing variability, positioning tool as a complement to existing assays.Work drew on a 5,841-patient development dataset, with additional evaluation in a prospective cohort of more than 3,400 cases, supporting potential commercial pull-through for MI Cancer Seek and Caris Molecular Tumor Board Report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4581wB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631489538","title":"Press Release: Horn Williamson Rebrands as Horn Williamson & Collins, Adds Matthew C. Collins as Named Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2631489538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631489538?lang=en_us&edition=fundamental","pubTime":"2026-04-29 03:54","pubTimestamp":1777406040,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Horn Williamson LLC today announced its rebrand to Horn Williamson & Collins, recognizing Matthew C. Collins as a named partner and marking the next stage in the firm's strategic growth.Collins joined the firm in 2021 and serves as chair of the firm's Community Association Group. He represents community associations throughout Pennsylvania and advises clients on governing documents, contract negotiation and drafting, transition matters, construction defect litigation, collections, director liability claims, real estate matters and commercial disputes. He is known for his practical, solutions-oriented approach and his ability to guide clients through complex matters.Collins maintains a longstanding relationship with the Community Associations Institute  Keystone Chapter and is actively involved in industry education. He is a frequent lecturer and panelist for management companies, board members and real estate professionals across the region.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAI","BK6027","BK4139","N32.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630805346","title":"A Look At Caris Life Sciences (CAI) Valuation As Shares Lose Momentum In Recent Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2630805346","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630805346?lang=en_us&edition=fundamental","pubTime":"2026-04-25 21:05","pubTimestamp":1777122316,"startTime":"0","endTime":"0","summary":"Why Caris Life Sciences Is On Investors’ Radar\nCaris Life Sciences (CAI) has attracted fresh attention after recent share price moves, with the stock up about 10% over the past month but showing a roughly 19% decline over the past 3 months.\nSee our latest analysis for Caris Life Sciences.\nThe recent 10.2% 30 day share price return stands against a 19.2% 90 day decline and a 25.1% year to date share price fall, indicating fading momentum despite the latest move.\nIf Caris’s recent swings have...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cai/caris-life-sciences/news/a-look-at-caris-life-sciences-cai-valuation-as-shares-lose-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","BK4528","CAI.AU","AGIX","CHAT","BK4023","BK4551","BK4588","CAI","BK4104","AIPO","BK4543","BK4585","BK4587","AIYY","AI","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629880871","title":"Caris Life Sciences announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629880871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629880871?lang=en_us&edition=fundamental","pubTime":"2026-04-23 18:26","pubTimestamp":1776939961,"startTime":"0","endTime":"0","summary":"Caris Life Sciences schedules 2026 annual shareholder meeting for June 4, 2026, to be held virtually.Shareholders will vote to elect 10 directors, including David Dean Halbert, Peter Castleman, Brian Brille.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL1RxqPy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728742","title":"Caris Life Sciences to report first-quarter financial results, host webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728742","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728742?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:31","pubTimestamp":1776688302,"startTime":"0","endTime":"0","summary":"Caris Life Sciences will report first-quarter 2026 financial results on May 7, 2026.Management will discuss results in a webcast at 3:30 p.m. CT on May 7, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbcZl73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4104","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111162445","title":"Hua An Insurance Announces CEO Resignation and Appointment of Interim Leader","url":"https://stock-news.laohu8.com/highlight/detail?id=1111162445","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111162445?lang=en_us&edition=fundamental","pubTime":"2026-04-17 15:31","pubTimestamp":1776411076,"startTime":"0","endTime":"0","summary":"On April 17, Hua An Property Insurance Co., Ltd. announced that Li Yunhuan has resigned from the position of company CEO due to personal reasons. In accordance with the resolution from the company's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAI","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627077984","title":"CAI Corp Updates Investors on March 2026 Net Asset Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2627077984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627077984?lang=en_us&edition=fundamental","pubTime":"2026-04-15 17:11","pubTimestamp":1776244306,"startTime":"0","endTime":"0","summary":"China New Economy Fund Ltd. ( ($HK:0080) ) has issued an update. CAI Corp, a Cayman Islands-incorporated company listed on the Hong Kong Stock Exch...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cai-corp-updates-investors-on-march-2026-net-asset-value?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cai-corp-updates-investors-on-march-2026-net-asset-value?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4104","CAI","BK4211","ISBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627413278","title":"U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2627413278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627413278?lang=en_us&edition=fundamental","pubTime":"2026-04-14 15:45","pubTimestamp":1776152709,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution MedicinesApril 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL4N40X0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEO","ADPT","CUBE","DLR","LNG","BE","FLS","BL","CBRE","BSX","HSY","GH","MSFU","BEX","TREE","CAG","CPB","IDYA","MSFY","PODD","EQIX","HUBS","MSFL","NTRA","MAA","BEG","GIS","CPT","SJM","MSFT","NSA","BRBR","WGS","ASAN","EXR","MSFD","AVB","MRNA","MSFO","MSFX","KHC","ADGM","CAI","JAN","BIIB","MRNX","BDX","MKC","INSP","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627453852","title":"Caris Life Sciences Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2627453852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627453852?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:33","pubTimestamp":1776083580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CAI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 08:33 ET (12:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAI","BK4139","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627378164","title":"Jefferies Initiates Caris Life Sciences at Buy With $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2627378164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627378164?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:19","pubTimestamp":1776079154,"startTime":"0","endTime":"0","summary":"Caris Life Sciences (CAI) has an average rating of buy and mean price target of $30.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":123,"code":"91000000","status":"200"}]}}